Systemic Sclerosis

November 18, 2019

Patients who have systemic sclerosis-associated interstitial lung disease and received nintedanib were more likely to have improved lung function than patients who received a placebo, according to a new study. Not only did nintedanib improve forced vital capacity, but patients who received the drug were less likely to experience declining clinical status and more likely to see their conditions stabilize.

September 12, 2019

A proof of concept clinical trial for riociguat (Adempas, Bayer) for patients with systemic sclerosis indicates that longer treatment periods may be necessary to heal digital ulcers. In this trial, the treatment wasn't effective in reducing the number of digital ulcers.

July 28, 2019

ACE inhibitors appear to heighten the risk of scleroderma renal crisis (SRC), a potentialy deadly complication in patients with systemic sclerosis.

June 10, 2019

Patients with systemic sclerosis-associated interstitial lung disease who also take nintedanib experience a lower drop in their forced vital capacity, according to a new study.

January 24, 2019

The focus here: early signs and symptoms that can point to the diagnosis.

June 22, 2018

A potential non-immunosuppressive treatment option for patients with diffuse cutaneous systemic sclerosis.

February 01, 2018

Highlights of 5 topline news stories from the FDA, CDC, and American College of Rheumatology-with real-world implications for primary care practice.

November 22, 2017

Compared with conventional treatment, extracorporeal shock-wave therapy resulted in a significant decrease in finger ulcers.

July 24, 2017

Low Bacteroidetes levels may suggest higher disease activity as in Crohn and other inflammatory diseases.

April 24, 2017

Research shows that for women with autoimmune disease, the increase risk of infection during pregnancy is associated with steroids, not DMARDs.